Proton Pump Inhibitors Market Research Report Information By Drug Type (Esomeprazole, Omeprazole, Dexlansoprazole, Pantoprazole, and Others), By Route of Administration (Oral, Injectable), By Indication (Gastroesophageal Reflux Disease, Heartburn, Peptic Ulcers, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Special Clinics) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Global Proton Pump Inhibitors Market Overview

Proton Pump Inhibitors Market Size was valued at USD 3.1 Billion in 2022. The Proton Pump Inhibitors market industry is projected to grow from USD 3.27 Billion in 2023 to USD 16.8 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.50% during the forecast period (2023 - 2032).Increasing over-the-counter (OTC) availability and healthcare investment are the key market drivers fueling the market growth.

Indication: Secondary Research, Primary Research, MRFR Database and Analyst Review

 Proton Pump Inhibitors Market Trends

• Increasing healthcare awareness is driving the market growth

 Market CAGR for Proton Pump Inhibitors is being driven by a growing healthcare awareness. Proton pump inhibitor (PPI) demand is rising as a result of increased awareness of healthcare issues, particularly those related to gastrointestinal health. People are more likely to seek medical attention for acid-related disorders when they are more aware of the efficaciousness of pharmaceutical solutions. This heightened consciousness not only promotes early intervention for gastrointestinal problems but also plays a major role in the general upsurge in PPI use. The trend is indicative of a larger change in patient behavior that emphasizes the value of prompt diagnosis and treatment, which will ultimately have a positive effect on the market for proton pump inhibitors as people become more health-conscious.

Proton pump inhibitors (PPIs) are in high demand due to the aging population, since a higher frequency of gastrointestinal problems is associated with an aging population. Acid-related disorders must be effectively managed because peptic ulcers and gastroesophageal reflux disease (GERD) are common in the elderly. As a result, PPIs—which are known to be effective in reducing stomach acid—become essential in managing these age-related health issues. PPIs are in greater demand as the aging population grows, which emphasizes the importance of these drugs in meeting the unique healthcare requirements of an elderly population that is more likely to experience gastrointestinal issues.

Some of the major factors that are positively influencing the market's growth during the forecast period include an increase in the prevalence of gastrointestinal disorders, an increase in the number of elderly people suffering from stomach disorders, an increase in gastroesophageal reflux disease, an increase in the consumption of unhealthy diets, a growing trend toward sedentary work cultures, an increase in the number of cases of obesity, and others. Current research indicates that the prevalence of GRED is estimated to be between 18.1% and 27.8% in North America, 8.8% to 25.9% in Europe, 2.5% to 7.8% in East Asia, 8.7% to 33.1% in the Middle East, 11.6% in Australia, and 23.0% in South America. Moreover, a growing number of manufacturers are accepting innovative drug delivery methods to grow the market. Thus, driving the Proton Pump Inhibitors market revenue.

Proton Pump Inhibitors Market Segment Insights

Proton Pump Inhibitors Drug Type Insights

The Proton Pump Inhibitors market segmentation, based on Drug Type includes Esomeprazole, Omeprazole, Dexlansoprazole, Pantoprazole, and Others. The Omeprazole segment dominated the market, accounting for 28% of market revenue (0.86 Billion). This is linked to Its effectiveness can be attributed to its widespread use and popularity among patients and healthcare professionals. The market is growing because omeprazole is widely accessible over-the-counter (OTC), allowing people to self-medicate for mild symptoms.

Figure 1: Proton Pump Inhibitors Market, by Drug Type, 2022 & 2032 (USD Billion)

Indication: Secondary Research, Primary Research, MRFR Database and Analyst Review

Proton Pump Inhibitors Route of Administration Insight

The Proton Pump Inhibitors market segmentation, based on the Route of Administration includes Oral and injectable. The Oral segment dominated the market, accounting for 66% (2.04 billion) of market revenue. One benefit of oral PPIs is that they enter the bloodstream and work systemically throughout the body. Oral drugs for GERD effectively lessen the production of stomach acid, ease esophageal inflammation, and encourage tissue repair. These drugs relieve symptoms and aid in the healing of the esophagus by blocking the enzyme that produces acid.

Proton Pump Inhibitors Indication Insights

 The Proton Pump Inhibitors market segmentation, based on Indication includes Gastroesophageal Reflux Disease, Heartburn, Peptic Ulcers, and Others. The Gastroesophageal Reflux Disease segment dominated the market, accounting for 49.5% (1.53 billion) of the market revenue. Proton pump inhibitor (PPI) demand is primarily driven by the rising incidence of GERD worldwide. A considerable section of the population suffers from GERD, a common medical condition. Numerous factors, including dietary practices, changes in lifestyle, and the rising incidence of obesity, are linked to the growing prevalence of GERD.

Proton Pump Inhibitors Distribution Channel Insights

The Proton Pump Inhibitors market segmentation, based on distribution channels includes Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Others. The hospital pharmacies segment dominated the market, accounting for 40% (1.24 Billion) of market revenue. Hospital pharmacies benefit from having a captive patient base and working closely with healthcare providers because of their direct connection to healthcare facilities. Patients with complicated medical conditions, such as those needing long-term PPI therapy, are frequently treated in hospitals.

Proton Pump Inhibitors Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific, and Rest of the World. The North American Proton Pump Inhibitors market area will dominate this market. The prevalence of GERD is increasing in the US, Canada, and Mexico as a result of people's shift to unhealthy lifestyles. An article in the Journal of annals of Esophagus from March 2022 states that 10–20% of Americans are affected by GERD symptoms every week, accounting for an estimated 40% of the country's population.

Further, the major countries studied in the market report are The US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: PROTON PUMP INHIBITORS MARKET SHARE BY REGION 2022 (USD Billion)

Indication: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe's Proton Pump Inhibitors market accounts for the second-largest market share because major players are concentrating more on getting approvals and releasing products. For example, in April 2018, MelTech melt-in-your-mouth technology, which dissolves the tablet without the need for water in the mouth, enabled the FDA to approve the novel omeprazole oral disintegrating tablet, omeprazole OD, which was launched by Perrigo Company plc and its partner, Dexcel Pharma Technologies, Ltd. An over-the-counter drug called omeprazole OD is used to treat heartburn. Further, the German Proton Pump Inhibitors market held the largest market share, and the UK Proton Pump Inhibitors market was the fastest-growing market in the European region

The Asia-Pacific Proton Pump Inhibitors Market is expected to grow at the fastest CAGR from 2023 to 2032. This is due to the need for efficient acid-suppressive drugs being driven by the rising aging population, the increasing prevalence of gastrointestinal disorders, and increased healthcare awareness.

Moreover, China’s Proton Pump Inhibitors market held the largest market share, and the Indian Proton Pump Inhibitors market was the fastest-growing market in the Asia-Pacific region.

Proton Pump Inhibitors Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development to expand their product lines, which will help the Proton Pump Inhibitors market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the Proton Pump Inhibitors industry must offer cost-effective items.

 Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Proton Pump Inhibitors industry to benefit clients and increase the market sector. In recent years, the Proton Pump Inhibitors industry has offered some of the most significant advantages to Consumers. Major players in the Proton Pump Inhibitors market, including Bayer AG, Cadila Pharmaceuticals, Cipla Limited, Dr. Reddy's Laboratories, Eisai Inc., GlaxoSmithKline PLC, Pfizer Inc., Perrigo Company PLC, Redhill Pharma Limited, Sanofi SA, Takeda Pharmaceuticals, and AstraZeneca, are attempting to increase market demand by investing in product development to increase their product line and Esomeprazoleer to diverse consumer needs.

AstraZeneca is a multinational pharmaceutical corporation committed to using cutting-edge medications to improve patient outcomes. Proton Pump Inhibitors (PPIs) are produced by AstraZeneca, a company well-known for its gastroenterology expertise. By lowering the production of stomach acid, PPIs like omeprazole and esomeprazole are frequently used to treat disorders like acid reflux and ulcers. PPIs are developed continuously thanks to AstraZeneca's dedication to research and development, offering efficient treatments for gastrointestinal issues. The company's pharmaceutical portfolio, which includes PPIs, addresses vital healthcare needs globally with an emphasis on patient well-being. In May 2023, AstraZeneca unveiled its most recent PPI innovation. They unveiled "ProtonEase XR," an extended-release tablet with a new PPI formulation that is intended to provide continuous acid suppression all day long. Patients can benefit from ProtonEase XR's convenience as it reduces the frequency of medication intake while maintaining reliable and efficient acid control.

A multinational pharmaceutical corporation well-known for its contributions to healthcare is Pfizer Inc. In addition to offering a wide range of pharmaceuticals, Pfizer has played a significant role in the development of proton pump inhibitors (PPIs), a class of medications that treat conditions related to stomach acid. PPIs work by preventing the production of stomach acid, as demonstrated by Pfizer's main product, which is intended to treat peptic ulcers and gastroesophageal reflux disease (GERD). These drugs are widely prescribed and effectively relieve millions of people worldwide, demonstrating Pfizer's dedication to developing innovative medical treatments and enhancing the quality of life for patients suffering from gastrointestinal disorders. In June 2023, Prominent pharmaceutical giant Pfizer Inc. declared that regulatory bodies had approved their recently developed proton pump inhibitor (PPI) drug. The drug, called "AcidGuard," is a next-generation proton pump inhibitor (PPI) with better safety and increased acid suppression.

Key Companies in the Proton Pump Inhibitors market include

• 
  

   AstraZeneca

  
  


• 
  

  Bayer AG

  
  


• 
  

  Cadila Pharmaceuticals

  
  


• 
  

  Eisai Inc.

  
  


• 
  

  GlaxoSmithKline PLC

  
  


• 
  

  Pfizer Inc.

  
  


• 
  

  Takeda Pharmaceuticals

  
  


• 
  

  Sanofi SA

  
  


• 
  

  Dr. Reddy’s Laboratories

  
  


• 
  

  Redhill Pharma Limited

  
  


• 
  

  Cipla Limited

  
  

Proton Pump Inhibitors Industry Developments

In January 2022:The US, TWI Pharmaceuticals USA introduced the generic version of Dexilant. It is a dexlansoprazole that is used to treat erosive esophagitis and heartburn brought on by GERD (Gastroesophageal reflux disease). Delxlansoprazole delayed release 30 mg and 60 mg capsules are the available dosages.

 April 2022:Escorten, one of the first proton-pump inhibitor medications, was introduced in Korea by Daewon Pharmaceutical. It is a 10 mg dose of magnesium trihydrate esomeprazole.

Proton Pump Inhibitors Market Segmentation

Proton Pump Inhibitors Drug Type Outlook

• 
  

  Esomeprazole

  
  


• 
  

  Omeprazole

  
  


• 
  

  Dexlansoprazole

  
  


• 
  

  Pantoprazole

  
  


• 
  

  Others

  
  

Proton Pump Inhibitors Route of Administration Outlook

• 
  

   Oral

  
  


• 
  

  Injectable

  
  

Proton Pump Inhibitors Indication Outlook

• 
  

   Gastroesophageal Reflux Disease

  
  


• 
  

  Heartburn

  
  


• 
  

  Peptic Ulcers

  
  


• 
  

  Others

  
  

Proton Pump Inhibitors Distribution Channel Outlook

• 
  

   Hospital Pharmacies

  
  


• 
  

  Retail Pharmacies

  
  


• 
  

  Drug Stores

  
  


• 
  

  Others

  
  

Proton Pump Inhibitors Regional Outlook

• 
  

  North America

  
  

• 
  

  US

  
  


• 
  

  Canada

  
  

• 
  

  Europe

  
  

• 
  

  Germany

  
  


• 
  

  France

  
  


• 
  

  UK

  
  


• 
  

  Italy

  
  


• 
  

  Spain

  
  


• 
  

  Rest of Europe

  
  

• 
  

  Asia-Pacific

  
  
  
  
  • 
    

    China

    
    
  
  
  • 
    

    Japan

    
    
  
  
  • 
    

    India

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    South Korea

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    Rest of Asia-Pacific

    
    
  
  
  
  


• 
  

  Rest of the World

  
  
  
  
  • 
    

    Middle East

    
    
  
  
  • 
    

    Africa

    
    
  
  
  • 
    

    Latin America